Eli Lilly Drug Combo Spurs Record Weight Loss In Diabetes Study

Participants Taking eloraTZP Lowered Their A1C By Up To Avg Of 2.9% Vs. 2.4% With Tirzepatide 15mg - At 48 Weeks, All Combinations Of eloraTZP Met Primary & Secondary Endpoints - Participants Taking eloraTZP Lost Up To Avg Of 54.1 Lbs (23.3%) Vs. 34.4lbs (14.8%) With Tirzepatide 15mg - Plans To Initiate Phase 3 Studies Of eloraTZP Co-Formulation Product By 2026 End Using Optimized Escalation Schedule